J 2026

Validation of the Zwolle Risk Score in STEMI Patients Undergoing Primary PCI: Insights from the ISCAS-STEMI COVID-19 Registry

GIUSEPPE, De Luca; Magdy ALGOWHARY; Berat UGUZ; Dinaldo C OLIVEIRA; Vladimir GANYUKOV et al.

Základní údaje

Originální název

Validation of the Zwolle Risk Score in STEMI Patients Undergoing Primary PCI: Insights from the ISCAS-STEMI COVID-19 Registry

Autoři

GIUSEPPE, De Luca; Magdy ALGOWHARY; Berat UGUZ; Dinaldo C OLIVEIRA; Vladimir GANYUKOV; Zan ZIMBAKOV; Miha CERCEK; Lisette Okkels JENSEN; Poay Huan LOH; Lucian CALMAC; Gerard FERRER; Alexandre QUADROS; Marek MILEWSKI; Di Uccio Fortunato SCOTTO; von Birgelen CLEMENS; Francesco VERSACI; Ten Berg JURRIEN; Gianni CASELLA; Aaron Wong Sung LUNG; Petr KALA; Diez Gil Jose LUIS; Xavier CARRILLO; Maurits T DIRKSEN; Victor Manuel BECERRA-MUNOZ; Michael Kang-yin LEE; Dafsah Arifa JUZAR; de Moura Joaquim RODRIGO; Roberto PALADINO; Davor MILICIC; Periklis DAVLOUROS; Nikola BAKRACESKI; Filippo ZILIO; Luca DONAZZAN; Adriaan KRAAIJEVELD; Gennaro GALASSO; Lux ARPAD; Lucia MARINUCCI; Vincenzo GUIDUCCI; Maurizio MENICHELLI; Alessandra SCOCCIA; Aylin Hatice YAMAC; Kadir Ugur MERT; Xacobe Flores RIOS; Tomas KOVARNIK; Michal KIDAWA; Jose MOREU; Flavien VINCENT; Enrico FABRIS; Inigo Lozano MARTINEZ-LUENGAS; Marco BOCCALATTE; Francisco Bosa OJEDA; Carlos ARELLANO-SERRANO; Gianluca CAIAZZO; Giuseppe CIRRINCIONE; Hsien-Li KAO; Juan Sanchis FORES; Luigi VIGNALI; Helder PEREIRA; Stephane MANZO-SILBERMANN; Santiago ORDONEZ; Alev Arat OZKAN; Bruno SCHELLER; Heidi LEHTOLA; Rui TELES; Christos MANTIS; Ylitalo ANTTI; Joao Antonio Brum SILVEIRA; Rodrigo ZONI; Ivan BESSONOV; Stefano SAVONITTO; George KOCHIADAKIS; Dimitrios ALEXOPOULOS; Carlos E URIBE; John KANAKAKIS; Benjamin FAURIE; Gabriele GABRIELLI; Alejandro Gutierrez BARRIOS; Juan Pablo BACHINI; Alex ROCHA; Frankie Chor-Cheung TAM; Alfredo RODRIGUEZ; Antonia Anna LUKITO; Veauthyelau SAINT-JOY; Gustavo PESSAH; Giuliana CORTESE; Guido PARODI; Mohammed Abed BURGADHA; Elvin KEDHI; Pablo LAMELAS; Harry SURYAPRANATA; Matteo NARDIN a Monica VERDOIA

Vydání

CURRENT VASCULAR PHARMACOLOGY, SHARJAH, BENTHAM SCIENCE PUBL LTD, 2026, 1570-1611

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.100 v roce 2024

Označené pro přenos do RIV

Ne

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Zwolle Risk Score; STEMI patients; COVID-19 registry; mechanical reperfusion; pandemic

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 3. 3. 2026 13:03, Mgr. Tereza Miškechová

Anotace

V originále

Background: Several scores have been developed to facilitate risk stratification and early discharge following primary angioplasty, particularly the Zwolle Risk Score (ZRS). However, validation in large-sized studies is still lacking. Therefore, the aim of the current study was to validate the use of the ZRS in a contemporary global population, including patients who were treated during the SARS-CoV-2 pandemic and enrolled in a large intercontinental observational study. Methods: The ISACS-STEMI COVID-19 is a large-scale retrospective multicenter registry involving primary PCI centers from Europe, Latin America, South-East Asia, and NorthAfrica, including patients treated from March 1st until June 30th, in 2019 and 2020]. ZRS was calculated for each patient. The patients were additionally categorized according to the following values of the ZRS [<= 3; 4-6; 7-9; >= 10]. Our study outcomes were in-hospital and 30-day mortality. The discriminatory capacity of the ZRS was assessed by the area under the ROC curve [c statistic] as an index of model performance. Results: Our population is represented by 16084 STEMI patients undergoing mechanical reperfusion enrolled in 109 centers. The score showed a very good performance in the predicting mortality both in-hospital [AUC=0.83 [0.82-0.85], p<0.0001] and at 30-day follow-up [AUC=0.82 [0.81-0.84, p<0.0001]. The results were confirmed when the ZRS was separately applied to patients treated in 2019 and 2020, with good stability across time. ZRS was able to identify a large cohort [n=10672, 66.3%] of low-risk patients [score <= 3] with a very low mortality rate at 2 days [1%] and between 3 and 10 days [0.7%], with a very good negative predictive value for in-hospital [98.3%] and 30-day mortality [97.7%], with similar results in 2019 and 2020. Conclusion: This study is the first to demonstrate the good prognostic performance of the ZRS in a large-scale contemporary global multicenter validation set. Similar results were obtained both in the pre-pandemic and the COVID-19 era. ZRS <= 3 identified a very low-risk population that could be discharged early, even during the COVID-19 pandemic, with expected advantages in the availability of hospital beds and nursing staff, costs of medical care, and in-hospital risk of contagion.